1. Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study.
- Author
-
UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Faivre, S, Niccoli, P, Castellano, D, Valle, J W, Hammel, P, Raoul, J-L, Vinik, A, Van Cutsem, E, Bang, Y-J, Lee, S-H, Borbath, Ivan, Lombard-Bohas, C, Metrakos, P, Smith, D, Chen, J-S, Ruszniewski, P, Seitz, J-F, Patyna, S, Lu, D R, Ishak, K J, Raymond, E, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Faivre, S, Niccoli, P, Castellano, D, Valle, J W, Hammel, P, Raoul, J-L, Vinik, A, Van Cutsem, E, Bang, Y-J, Lee, S-H, Borbath, Ivan, Lombard-Bohas, C, Metrakos, P, Smith, D, Chen, J-S, Ruszniewski, P, Seitz, J-F, Patyna, S, Lu, D R, Ishak, K J, and Raymond, E
- Abstract
In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved investigator-assessed progression-free survival (PFS) versus placebo (11.4 vs. 5.5 months; HR, 0.42; P < 0.001). Here, we present PFS using retrospective blinded independent central review (BICR) and final median overall survival (OS), including an assessment highlighting the impact of patient crossover from placebo to sunitinib.
- Published
- 2016